|
Genentech makes pertuzumab, herceptin and Tarceva
Tarceva is a tyrosine kinase inhibitor of EGFR like IRESSA is. Trying to get different drug companies to cooperate in a clinical trial can be difficult, but perhaps Genentech would be interested in a trial of three of their products.
There is going to be an interesting conference on the biological basis of breast cancer at the end of June with Francisco Esteva, Laszlo Pusztai (sorry about spelling), Carlos Arteaga, Mark Pegram, etc who think deeply about how all the her2 groups interact. It will be held in Santa Monica and will probably be quite
detailed in the molecular biology of breast cancer. These researchers as well as Martine Piccart and Edith Perez as well as George Sledge, Neil Spector and, of course, Dr. Slamon are all truly interested in the multipronged attack necessary in individual breast cancer treatment which is directed and targetted against the molecular "bad actors" driving each particular cancer.
Susan Desmond-Helman(sorry about my spelling--chief scientific officer) and
Pamela Klein (in charge of herceptin) might be good people to ask whether Genentech is interested in starting up such trials
.
Hopefully the length of treatment required with three agents is far shorter than that required with one, or the cost will end up prohibitive.
Am off in the am for Denmark, so may not join back in for a while (until jet lag recovered from and computer setup sorted out)
|
Threaded Mode